uniQure N.V. (QURE) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
uniQure N.V. (QURE) Profile & Business Summary
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Key Information
| Ticker | QURE |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.uniqure.com |
Market Trend Overview for QURE
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-07-13 (ET)
As of 2026-07-13, QURE is showing signs of slowing down. Over the longer term, the trend remains bullish.
QURE last closed at 41.10. The price is about 1.3 ATR below its recent average price (43.57), and the market is currently in a trend that may be losing strength. Price at 41.10 is near minor support around 39.50. Momentum may slow, while minor resistance sits near 45.70. View Support & Resistance from Options
The broader uptrend is still intact, but price has moved far from its recent average, increasing the risk of a pullback.
Trend score: 55 out of 100. Overall alignment is unclear. The market is currently in a late-stage trend that may be losing strength. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside risk boundary is near 31.12. If price falls below this area, the current structure would likely weaken further.
On 2026-07-02, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-06-16] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
The model sees a bearish edge, but still treats it as a selective downside setup rather than an aggressive downside call.
Up probability is only 43.8%, with predictability at 48% and agreement at 88%. Reversal risk is 14%. That suggests downside pressure is present, while the setup still remains selective rather than extreme. At the same time, recent price behavior has shown failed reversal memory.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is trading 8.4% below the recent estimated cost basis of 44.87, so the recent structure is still leaning under pressure. Price is below the main cost band (46.68 to 48.88), and roughly 88% of recent positioning remains under water. That means rebounds can still run into supply from trapped holders. The broader structure still looks stretched on the weak side, so recovery attempts may need more proof before improving the tone. The higher up selling area sits around 43.07 to 43.37, so rebounds may begin to slow as price pushes into that zone. The main cost band is fairly wide relative to recent ATR, so this structure may behave less cleanly than a tighter setup. From a trading point of view, this setup remains tougher until price can reclaim the lower edge of the main cost band near 46.68.